Literature DB >> 10372832

Activation of nitric oxide synthase by beta 2-adrenoceptors in human umbilical vein endothelium in vitro.

A Ferro1, L R Queen, R M Priest, B Xu, J M Ritter, L Poston, J P Ward.   

Abstract

1. Some animal studies suggest that beta-adrenoceptor-mediated vasorelaxation is in part mediated through nitric oxide (NO) release. Furthermore, in humans, we have recently shown that forearm blood flow is increased by infusion of beta2-adrenergic agonists into the brachial artery, and the nitric oxide synthase (NOS) inhibitor N(G)-monomethyl-L-arginine (L-NMMA) inhibits this response. 2. The purpose of the present study was to determine whether stimulation of human umbilical vein endothelial beta-adrenoceptors causes vasorelaxation and nitric oxide generation, and whether this might be mediated by cyclic adenosine-3',5'-monophosphate (cyclic AMP). 3. Vasorelaxant responses were determined in umbilical vein rings to the nonselective beta-adrenergic agonist isoprenaline and to the cyclic AMP analogue dibutyryl cyclic AMP, following precontraction with prostaglandin F2alpha. 4. NOS activity was measured in cultured human umbilical vein endothelial cells (HUVEC) by the conversion of [3H]-L-arginine to [3H]-L-citrulline, and adenylyl cyclase activity by the conversion of [alpha-32P]-ATP to [32P]-cyclic AMP. 5. Isoprenaline relaxed umbilical vein rings, and this vasorelaxation was abolished by beta2- (but not beta1-) adrenergic blockage, and by endothelium removal or 1 mM L-NMMA. In addition, vasorelaxant responses to dibutyryl cyclic AMP were inhibited by 1 mM L-NMMA, with a reduction in Emax from 90.0+/-9.3% to 50.5+/-9.9% (P<0.05). 6. Isoprenaline 1 microM increased NOS activity in HUVEC (34.0+/-5.9% above basal, P<0.001). Furthermore, isoprenaline increased adenylyl cyclase activity in a concentration-dependent manner; this response was inhibited by beta2 (but not beta1-) adrenergic blockade. Forskolin 1 microM and dibutyryl cyclic AMP 1 mM each increased NOS activity in HUVEC, to a degree similar to isoprenaline 1 microM. The increase in L-arginine to L-citrulline conversion observed with each agent was abolished by coincubation with NOS inhibitors. 7. These results indicate that endothelial beta2-adrenergic stimulation and cyclic AMP elevation activate the L-arginine/NO system, and give rise to vasorelaxation, in human umbilical vein.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10372832      PMCID: PMC1565965          DOI: 10.1038/sj.bjp.0702512

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  44 in total

1.  A highly sensitive adenylate cyclase assay.

Authors:  Y Salomon; C Londos; M Rodbell
Journal:  Anal Biochem       Date:  1974-04       Impact factor: 3.365

2.  Endothelial cells contain beta adrenoceptors.

Authors:  S F Steinberg; E A Jaffe; J P Bilezikian
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1984-04       Impact factor: 3.000

3.  Effects of inhibition of the L-arginine/nitric oxide pathway on vasodilation caused by beta-adrenergic agonists in human forearm.

Authors:  M Dawes; P J Chowienczyk; J M Ritter
Journal:  Circulation       Date:  1997-05-06       Impact factor: 29.690

4.  The pharmacology of a beta 2-selective adrenoceptor antagonist (ICI 118,551).

Authors:  A J Bilski; S E Halliday; J D Fitzgerald; J L Wale
Journal:  J Cardiovasc Pharmacol       Date:  1983 May-Jun       Impact factor: 3.105

Review 5.  Factors modifying contraction-relaxation cycle in vascular smooth muscles.

Authors:  H Kuriyama; Y Ito; H Suzuki; K Kitamura; T Itoh
Journal:  Am J Physiol       Date:  1982-11

6.  Endothelium-removal decreases relaxations of canine coronary arteries caused by beta-adrenergic agonists and adenosine.

Authors:  G Rubanyi; P M Vanhoutte
Journal:  J Cardiovasc Pharmacol       Date:  1985 Jan-Feb       Impact factor: 3.105

7.  A caveolar complex between the cationic amino acid transporter 1 and endothelial nitric-oxide synthase may explain the "arginine paradox".

Authors:  K K McDonald; S Zharikov; E R Block; M S Kilberg
Journal:  J Biol Chem       Date:  1997-12-12       Impact factor: 5.157

8.  Direct labelling of beta 2-adrenoceptors. Comparison of binding potency of 3H-ICI 118,551 and blocking potency of ICI 118,551.

Authors:  H Lemoine; B Ehle; A J Kaumann
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1985-10       Impact factor: 3.000

9.  Autoradiographic localization and function of beta-adrenoceptors on the human internal mammary artery and saphenous vein.

Authors:  P Molenaar; E Malta; C R Jones; B F Buxton; R J Summers
Journal:  Br J Pharmacol       Date:  1988-09       Impact factor: 8.739

10.  The beta 1-adrenoceptor antagonist CGP 20712 A unmasks beta 2-adrenoceptors activated by (-)-adrenaline in rat sinoatrial node.

Authors:  A J Kaumann
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1986-04       Impact factor: 3.000

View more
  46 in total

1.  Essential role of L-arginine uptake and protein tyrosine kinase activity for NO-dependent vasorelaxation induced by stretch, isometric tension and cyclic AMP in rat pulmonary arteries.

Authors:  D Hucks; N M Khan; J P Ward
Journal:  Br J Pharmacol       Date:  2000-12       Impact factor: 8.739

2.  The role of nitric oxide synthase in reduced vasocontractile responsiveness induced by prolonged alpha1-adrenergic receptor stimulation in rat thoracic aorta.

Authors:  Hakan Gürdal; Alp Can; Mehmet Uğur
Journal:  Br J Pharmacol       Date:  2005-05       Impact factor: 8.739

Review 3.  Vascular large conductance calcium-activated potassium channels: functional role and therapeutic potential.

Authors:  Birgit Eichhorn; Dobromir Dobrev
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2007-10-12       Impact factor: 3.000

4.  Methods in clinical pharmacology.

Authors:  J M Ritter
Journal:  Br J Clin Pharmacol       Date:  2009-07       Impact factor: 4.335

5.  Mechanisms underlying beta2-adrenoceptor-mediated nitric oxide generation by human umbilical vein endothelial cells.

Authors:  Lindsay R Queen; Yong Ji; Biao Xu; Lora Young; Kang Yao; Amanda W Wyatt; David J Rowlands; Richard C M Siow; Giovanni E Mann; Albert Ferro
Journal:  J Physiol       Date:  2006-07-27       Impact factor: 5.182

Review 6.  GRK2 as negative modulator of NO bioavailability: Implications for cardiovascular disease.

Authors:  Alessandro Cannavo; Walter J Koch
Journal:  Cell Signal       Date:  2017-01-07       Impact factor: 4.315

7.  Postnatal changes in beta-adrenoceptors in the lung and the effect of hypoxia induced pulmonary hypertension of the newborn.

Authors:  Alison A Hislop; Judith C W Mak; David Kelly; Jayne A Reader; Peter J Barnes; Sheila G Haworth
Journal:  Br J Pharmacol       Date:  2002-03       Impact factor: 8.739

8.  A novel role for an endothelial adrenergic receptor system in mediating catecholestradiol-induced proliferation of uterine artery endothelial cells.

Authors:  Sheikh O Jobe; Sean N Fling; Jayanth Ramadoss; Ronald R Magness
Journal:  Hypertension       Date:  2011-09-26       Impact factor: 10.190

9.  Hydroxyurea nitrosylates and activates soluble guanylyl cyclase in human erythroid cells.

Authors:  Vladan P Cokic; Silvana A Andric; Stanko S Stojilkovic; Constance T Noguchi; Alan N Schechter
Journal:  Blood       Date:  2007-11-09       Impact factor: 22.113

10.  Nitric oxide-dependent beta2-adrenergic dilatation of rat aorta is mediated through activation of both protein kinase A and Akt.

Authors:  Albert Ferro; Marcy Coash; Takahiro Yamamoto; Jubli Rob; Yong Ji; Lindsay Queen
Journal:  Br J Pharmacol       Date:  2004-09-06       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.